Fedratinib in 2025 and beyond: indications and future applications
Abstract: Dysregulated JAK/STAT signaling underlies the pathogenesis of myelofibrosis, a myeloproliferative neoplasm characterized by cytopenias, splenomegaly, and constitutional symptoms. JAK inhibitors, such as fedratinib, are the primary therapeutic option for patients with high-risk or symptomat...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2025-04-01
|
| Series: | Blood Advances |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S2473952925001041 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|